Panelists review a patient case of a 45 year old man with high-risk T4N0 resected CRC.

Panelists discuss important patient counseling points regarding ctDNA results in colorectal cancer (CRC), focusing on how to communicate the implications of these results for treatment decisions, prognosis, and personalized care planning.

Panelists discuss how the CIRCULATE study's GALAXY results demonstrate the potential impact of circulating tumor DNA analysis in guiding adjuvant therapy decisions for stage II colon cancer patients, though further validation is needed before widespread clinical implementation.

Panelists discuss how patterns of ctDNA clearance in resected colorectal cancer patients - whether transient or sustained - can inform prognosis, guide treatment decisions, and predict disease recurrence risk.

Panelists discuss how to navigate real-world challenges in implementing ctDNA testing for colorectal cancer patients, including issues of test accessibility, result interpretation, insurance coverage, and integration into clinical workflows.

Panelists discuss how the NICHE-2 trial results demonstrate the potential benefits and implementation of neoadjuvant immunotherapy in patients with dMMR colon cancer, highlighting pathologic response rates and implications for treatment sequencing.

Panelists discuss how Minimal Residual Disease (MRD) and circulating tumor DNA (ctDNA) testing are revolutionizing colon cancer management through improved risk stratification, treatment selection, and surveillance strategies.